Medincell SA
MEDCL
Company Profile
Business description
Medincell SA is a clinical- and commercial-stage biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, combining its proprietary BEPO technology with active ingredients already known and marketed. Its product portfolio includes UZEDY, mdc-TJK (Olanzapine LAI) and mdc-CWM (intra-articular celecoxib). The Company has a single operating segment: the conduct of research and development on biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals.
Contact
3 rue des Freres Lumiere
Jacou34830
FRAT: +33 467021367
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
150
Stocks News & Analysis
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
stocks
Our view after Coles’ shares plunge
Shares dropped 8% after reporting results for the September 2026 quarter.
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,977.20 | 48.20 | -0.53% |
| CAC 40 | 8,047.69 | 78.27 | 0.98% |
| DAX 40 | 25,981.09 | 162.88 | 0.63% |
| Dow JONES (US) | 51,983.98 | 213.67 | 0.41% |
| FTSE 100 | 10,761.33 | 31.55 | 0.29% |
| HKSE | 23,393.32 | 98.90 | 0.42% |
| NASDAQ | 25,164.31 | 272.68 | -1.07% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,649.52 | 49.11 | -0.36% |
| S&P 500 | 7,541.40 | 38.67 | -0.51% |
| S&P/ASX 200 | 8,856.50 | 51.60 | -0.58% |
| SSE Composite Index | 3,638.03 | 39.01 | 1.08% |